沙库巴曲缬沙坦对高血压合并HFpEF影响研究的进展

Research progress on influence of sacubitril valsartan on hypertension complicated with HFpEF

沙库巴曲缬沙坦(又名沙库比曲缬沙坦)是目前指南推荐治疗心衰(HF)的新型药物,与血管紧张素转换酶抑制剂和血管紧张素受体拮抗剂相比,沙库巴曲缬沙坦有更好的安全性和耐受性。沙库巴曲缬沙坦可对高血压患者进行降压的同时逆转早期心室肥厚,延缓HF进程。本文就沙库巴曲缬沙坦对高血压合并射血分数保留的HF影响的研究进展作一综述。

Sacubitril valsartan is a new drug recommended in the current guidelines for treatment of heart failure(HF),and it possesses better safety and tolerance than angiotensin converting enzyme inhibitor and angiotensin receptor blocker.Sacubitril valsartan can reduce blood pressure in hypertensive patients while reversing early ventricular hypertrophy and delaying HF progress.The present article makes a review on research progress on influence of sacubitril valsartan on hypertension complicated HF with preserved ejection fraction.